Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited ...
Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...
Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback